-
公开(公告)号：EP3443954A1
公开(公告)日：2019-02-20
申请号：EP17781942.2
申请日：2017-04-14
发明人： GU, Hongmei , WANG, Shanchun , ZHANG, Xiquan , HUANG, Lei , XU, Hongjiang , SONG, Wei , DONG, Ping , SUN, Zhongying , ZHANG, Ying , CHEN, Deyang
IPC分类号： A61K9/72 , A61K9/12 , A61K31/704 , A61P1/16 , A61P31/12
摘要： The present invention belongs to the field of medicine, relates to an inhaled preparation of isoglycyrrhizic acid or a salt thereof, and in particular relates to an inhaled preparation of magnesium isoglycyrrhizinate and the use thereof in preparing drugs for treating respiratory system diseases.
-
公开(公告)号：EP3858832A1
公开(公告)日：2021-08-04
申请号：EP19878278.1
申请日：2019-10-29
发明人： LIU, Fei , FENG, Weiwei , WANG, Bin , XU, Hongjiang , WANG, Jinan , ZHANG, Xiquan , WANG, Shanchun , LIU, Yanlong , ZHANG, Jianqing , YAO, Yiyan , TANG, Xujing , SHI, Wei , ZHANG, Hongying , LI, Yang , TANG, Song , ZHU, Yizhong , LIU, Limin , GU, Hongmei , YANG, Ling
IPC分类号： C07D471/04 , C07D211/96 , C07D215/20 , A61K31/404 , A61P35/00
摘要： Disclosed is a trifluoromethyl-substituted sulfonamide BCL-2-selective inhibitor, in particular disclosed are a compound of formula I, a stereoisomer or a pharmaceutically acceptable salt thereof, a preparation method therefor, and a pharmaceutical composition thereof. Also disclosed are the uses of said compound and of a pharmaceutical composition comprising same for treating anti-apoptotic BCL-2-related diseases, such as cancer.
-
公开(公告)号：EP3272746B1
公开(公告)日：2019-12-25
申请号：EP16767717.8
申请日：2016-03-18
申请人： Chia Tai Tianqing Pharmaceutical Group Co., Ltd. , Centaurus BioPharma Co., Ltd. , Lianyungang Runzhong Pharmaceutical Co., Ltd.
发明人： ZHANG, Xiquan , TANG, Song , FENG, Weiwei , TIAN, Xin , CHEN, Zhilin , GU, Hongmei , XU, Hongjiang , LIU, Fei
IPC分类号： C07D403/12 , C07D401/12 , C07D405/14 , A61K31/517 , A61K31/5377 , A61P35/00 , A61K31/4427 , A61K45/06 , C07D239/94 , C07D211/40
-
公开(公告)号：EP3919485A1
公开(公告)日：2021-12-08
申请号：EP20749295.0
申请日：2020-01-31
发明人： ZHANG, Xiquan , WANG, Shanchun , GENG, Wenjun , LIU, Yanlong , ZHANG, Huihui , LIU, Fei , ZHU, Shanliang , LI, Xinlu , ZHAO, Rui , GU, Hongmei
IPC分类号： C07D401/12 , A61P35/00 , A61K31/4709
摘要： The present application relates to the field of medicine, and relates to crystals of quinoline derivatives, and in particular, to crystals of a quinoline derivative anhydride and a solvate, as well as a method for preparing the crystals, pharmaceutical compositions containing the crystals, and a use thereof in the field of medicine. The present application further provides a preparation method therefor, which has a high yield, has mild crystallization conditions, is suitable for industrial production, and may better meet the needs of the pharmaceutical industry.
-
5.发明公开METHOD FOR TREATING TUMOUR, PHARMACEUTICAL COMPOSITION AND MEDICINE BOX KIT 审中-公开法肿瘤的治疗和药物组合物MEDIZINKASTENKIT
公开(公告)号：EP3153169A1
公开(公告)日：2017-04-12
申请号：EP15803424.9
申请日：2015-06-05
发明人： WANG, Shanchun , WANG, Xunqiang , GU, Hongmei , DONG, Ping , XU, Hongjiang
IPC分类号： A61K31/4709 , A61K9/20 , A61K9/48 , A61P35/00
摘要： The present invention provides 1-[[[4-(4-fluoro-2-methyl-1H-indol-5-yl)oxy-6-methoxyquinolin-7-yl]oxy]methyl]cyclopro-pylamine used for combating a tumor. Specially, the present invention refers to method for treating tumor, pharmaceutical composition and medicinal kit related to the described compound. Administrating the compound with a suitable dosage regimen can not only make the patient's plasma concentration maintain the level of 100 ng/ml or lower, but also achieve effects of treatments and obtain benefits for various tumours.
摘要翻译： 本发明提供了1 - [[[4-（4-氟-2-甲基-1H-吲哚-5-基）氧基-6-甲氧基喹啉-7-基]氧基]甲基]用于防治肿瘤cyclopro-pylamine ， 特别地，本发明涉及一种用于治疗肿瘤，药物组合物和药用试剂盒相关的所描述的化合物。 施用与合适的剂量方案的化合物不仅可以使患者的血浆浓度保持100毫微克/毫升或更低的水平，从而实现但治疗效果，并获得关于各种肿瘤的好处。
-
公开(公告)号：EP3153169B1
公开(公告)日：2020-08-05
申请号：EP15803424.9
申请日：2015-06-05
发明人： WANG, Shanchun , WANG, Xunqiang , GU, Hongmei , DONG, Ping , XU, Hongjiang
IPC分类号： A61K31/4709 , A61K9/20 , A61K9/48 , A61P35/00
-
公开(公告)号：EP3476841A1
公开(公告)日：2019-05-01
申请号：EP17814745.0
申请日：2017-06-23
申请人： Chia Tai Tianqing Pharmaceutical Group Co., Ltd. , Lianyungang Runzhong Pharmaceutical Co., Ltd. , Centaurus BioPharma Co., Ltd.
发明人： ZHU, Yizhong , TANG, Jianqiu , LIU, Fei , ZHANG, Xiquan , GU, Hongmei , ZHU, Bo , WANG, Lulu , TANG, Song , ZHANG, Yanyang
IPC分类号： C07D403/04 , A61K31/506 , A61P35/00 , A61P35/02
摘要： The present application belongs to the field of medicinal chemistry, and relates to crystals of an aniline pyrimidine compound serving as an EGFR inhibitor. Specifically, the present application relates to crystal A, crystal B and crystal C of N-(2-((2-(dimethyl amino)ethyl)(methyl)amino)-4-methoxy-5-(4-(3-methyl-2-oxo-2,3-dihydro-1H-benzo[d]imidazole-1-base)pyrimidine-2-base amino)phenyl)acrylamide (formula I) hydrochloride, and also relates to the method for preparing the crystal A, the crystal B and the crystal C, a crystal composition comprising the crystal A, the crystal B, and the crystal C, a pharmaceutical composition comprising the crystal A, the crystal B and the crystal C or the crystal composition thereof, and medical uses thereof. The crystal A, the crystal B and the crystal C in the present application has the advantages of high purity, high crystallization degree, good stability and the like.
-
-
-
-
-
-
搜索结果
7 条记录 (耗时 0.011 秒)
